Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $79.2M bought by 61 insiders at 47 companies
  • $239M sold by 49 insiders outside a trading plan
  • $2.5B sold by 203 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past week, each insider's filings added up.

  1. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    1,430,631 shares at $34.37 Oct 15–21, 5 filings +1.1% to stake 2 superinvestors bought in Q2
    $49.2M
  2. DOLEDole PLC
    Pale Fire Capital SE10% owner, +4 joint filers
    648,356 shares at $13.19 Oct 20–22 +6.7% to stake
    $8.6M
  3. APLDApplied Digital
    Jason Gechen ZhangPresident
    300,000 shares at $18.86 Oct 16 +12% to stake 5 superinvestors bought in Q2
    $5.7M
  4. RENTRent the Runway
    STORY3 Capital Partners, LLCDirector, +3 joint filers
    632,922 shares at $3.55 Oct 21 +15% to stake
    $2.2M
  5. RENTRent the Runway
    CHS US Investments LLC10% owner, +4 joint filers
    458,245 shares at $3.55 Oct 21 +2% to stake
    $1.6M
  6. FBKFB Financial
    Orrin H Ingram IIDirector
    29,081 shares at $52.88 Oct 20 +31% to stake
    $1.5M
  7. TENXTenax Therapeutics
    ADAR1 Capital Management, LLC10% owner, +1 joint filer
    922,849 shares at $1.59 Oct 19–21 +14% to stake
    $1.5M
  8. APLDApplied Digital
    Wes CumminsCEO
    55,803 shares at $18.04 Oct 16 +1% to stake 5 superinvestors bought in Q2
    $1M
  9. RAPPRapport Therapeutics
    Steven M PaulDirector
    35,714 shares at $27.28 Oct 22 +86% to stake
    $974K
  10. SNESSenesTech
    Glenbrook Capital Management10% owner
    1,087,679 shares at $0.7200 Oct 15–22, 2 filings
    $781K

Biggest sales

Past week, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    43,111 shares at $46,654.38 Oct 20 0.5% of stake Planned sale (10b5-1)
    $2B
  2. SNOWSnowflake
    Frank SlootmanDirector
    300,000 shares at $316.43 Oct 19 94% of stake Planned sale (10b5-1)
    $94.9M
  3. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    4,893,590 shares at $17.55 Oct 15–19, 2 filings 17% of stake
    $85.9M
  4. TRVTravelers
    Alan D SchnitzerCEO
    88,900 shares at $396.77 Oct 21 23% of stake
    $35.3M
  5. PATHUiPath
    Daniel DinesCEO
    2,500,000 shares at $13.23 Oct 15–16 7.9% of stake Planned sale (10b5-1)
    $33.1M
  6. UTHRUnited Therapeutics
    Martine A RothblattCEO
    47,500 shares at $555.06 Oct 16–22, 5 filings 13% of stake Planned sale (10b5-1)
    $26.4M
  7. MUMicron Technology
    Scott J DeboerPres. & Chief Tech & Prod Offr
    28,545 shares at $900.00 Oct 16 16% of stake Planned sale (10b5-1)
    $25.7M
  8. ALMRAlamar Biosciences
    Qiming Corporate GP VI, Ltd.10% owner, +6 joint filers
    733,811 shares at $28.64 Oct 15–22, 3 filings 29% of stake
    $21M
  9. SNOWSnowflake
    Benoit DagevilleDirector
    50,000 shares at $321.74 Oct 21 2.1% of stake Planned sale (10b5-1)
    $16.1M
  10. LINDLindblad Expeditions
    Sven-Olof LindbladDirector
    403,674 shares at $35.31 Oct 16–22, 2 filings 3.8% of stake Planned sale (10b5-1)
    $14.3M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

HOWL insider trades

Every open-market buy and sale in HOWL, one row per filing, newest first

HOWL page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $45K 143,199 shares at $0.3100 100% of stake
    Traded Jul 6–7 Filed Jul 8
    ↗
  2. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $47K 157,084 shares at $0.3000 52% of stake
    Traded Jun 29 Filed Jun 29
    ↗
  3. Ra Capital Management, L.P. 10% owner, +3 joint filers
    HOWLWerewolf Therapeutics
    Sale
    $146K 416,911 shares at $0.3500 58% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  4. Ra Capital Management, L.P. 10% owner, +3 joint filers
    HOWLWerewolf Therapeutics
    Sale
    $174K 448,836 shares at $0.3900 58% of stake
    Traded Jun 12–16 Filed Jun 16
    ↗
  5. Ra Capital Management, L.P. 10% owner, +3 joint filers
    HOWLWerewolf Therapeutics
    Sale
    $254K 678,226 shares at $0.3700 65% of stake
    Traded Jun 9–11 Filed Jun 11
    ↗
  6. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $28K 76,928 shares at $0.3700 20% of stake
    Traded Jun 9 Filed Jun 10
    ↗
  7. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $43K 105,565 shares at $0.4100 22% of stake
    Traded Jun 4–8 Filed Jun 8
    ↗
  8. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $64K 139,803 shares at $0.4600 23% of stake
    Traded Jun 1–3 Filed Jun 3
    ↗
  9. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $66K 141,106 shares at $0.4700 19% of stake
    Traded May 27–29 Filed May 29
    ↗
  10. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $87K 191,762 shares at $0.4500 20% of stake
    Traded May 21–26 Filed May 26
    ↗
  11. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $76K 171,049 shares at $0.4500 15% of stake
    Traded May 18–20 Filed May 20
    ↗
  12. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $24K 44,679 shares at $0.5400 3.8% of stake
    Traded May 13 Filed May 13
    ↗
  13. Ra Capital Management, L.P. 10% owner, +3 joint filers
    HOWLWerewolf Therapeutics
    Sale
    $391K 565,167 shares at $0.6900 58% of stake
    Traded May 8–12 Filed May 12
    ↗
  14. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $280K 407,574 shares at $0.6900 26% of stake
    Traded May 8–12 Filed May 12
    ↗
  15. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $64K 100,581 shares at $0.6400 6% of stake
    Traded May 5–7 Filed May 7
    ↗
  16. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $198K 274,619 shares at $0.7200 14% of stake
    Traded Apr 30–May 4 Filed May 4
    ↗
  17. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $155K 205,911 shares at $0.7500 9.5% of stake
    Traded Apr 27–29 Filed Apr 29
    ↗
  18. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $21K 38,782 shares at $0.5400 1.8% of stake
    Traded Jan 16 Filed Jan 20
    ↗
  19. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $62K 111,227 shares at $0.5600 4.8% of stake
    Traded Jan 13–15 Filed Jan 15
    ↗
  20. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $54K 91,374 shares at $0.5900 3.8% of stake
    Traded Jan 8–12 Filed Jan 12
    ↗
  21. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $46K 71,054 shares at $0.6500 2.9% of stake
    Traded Jan 5–7 Filed Jan 7
    ↗
  22. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $48K 78,377 shares at $0.6200 3.1% of stake
    Traded Dec 30, 2025–Jan 2 Filed Jan 2
    ↗
  23. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $185K 291,283 shares at $0.6400 10% of stake
    Traded Dec 22–29 Filed Dec 29, 2025
    ↗
  24. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $52K 48,171 shares at $1.08 1.7% of stake
    Traded Dec 15–17 Filed Dec 17, 2025
    ↗
  25. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $89K 82,971 shares at $1.07 2.8% of stake
    Traded Dec 10–12 Filed Dec 12, 2025
    ↗
  26. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $95K 95,179 shares at $1.00 3.1% of stake
    Traded Dec 5–9 Filed Dec 9, 2025
    ↗
  27. MPM BioVentures 2014, L.P. Insider, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $183K 199,732 shares at $0.9200 4% of stake
    Traded Dec 2–4 Filed Dec 4, 2025
    ↗
  28. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $118K 128,185 shares at $0.9200 4% of stake
    Traded Dec 2–4 Filed Dec 4, 2025
    ↗
  29. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $137K 141,927 shares at $0.9600 2.8% of stake
    Traded Nov 26, 2025–Dec 1, 2025 Filed Dec 1, 2025
    ↗
  30. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $88K 91,088 shares at $0.9600 2.8% of stake
    Traded Nov 26, 2025–Dec 1, 2025 Filed Dec 1, 2025
    ↗
  31. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $180K 195,666 shares at $0.9200 3.7% of stake
    Traded Nov 21–25 Filed Nov 25, 2025
    ↗
  32. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $115K 125,576 shares at $0.9200 3.7% of stake
    Traded Nov 21–25 Filed Nov 25, 2025
    ↗
  33. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $148K 160,103 shares at $0.9200 2.9% of stake
    Traded Nov 18–20 Filed Nov 20, 2025
    ↗
  34. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $95K 102,753 shares at $0.9200 2.9% of stake
    Traded Nov 18–20 Filed Nov 20, 2025
    ↗
  35. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $201K 209,652 shares at $0.9600 3.7% of stake
    Traded Nov 13–17 Filed Nov 17, 2025
    ↗
  36. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $129K 134,553 shares at $0.9600 3.7% of stake
    Traded Nov 13–17 Filed Nov 17, 2025
    ↗
  37. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $241K 213,529 shares at $1.13 3.6% of stake
    Traded Nov 7–12 Filed Nov 12, 2025
    ↗
  38. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $155K 137,041 shares at $1.13 3.6% of stake
    Traded Nov 7–12 Filed Nov 12, 2025
    ↗
  39. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $296K 242,890 shares at $1.22 4% of stake
    Traded Nov 4–6 Filed Nov 6, 2025
    ↗
  40. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $190K 155,885 shares at $1.22 4% of stake
    Traded Nov 4–6 Filed Nov 6, 2025
    ↗
  41. MPM BioVentures 2014, L.P. 10% owner, +4 joint filers
    HOWLWerewolf Therapeutics
    Planned sale
    $392K 295,043 shares at $1.33 4.6% of stake
    Traded Oct 30, 2025–Nov 3, 2025 Filed Nov 3, 2025
    ↗
  42. Luke Evnin Director
    HOWLWerewolf Therapeutics
    Planned sale
    $251K 189,356 shares at $1.33 4.6% of stake
    Traded Oct 30, 2025–Nov 3, 2025 Filed Nov 3, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.